Day: January 4, 2021

– Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) –RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of William C. Roberts as its Vice President, Investor Relations & Corporate Communications.“We are excited to announce the addition of Will to the G1 Therapeutics executive team,” said Jack Bailey, Chief Executive Officer of G1 Therapeutics. “His deep experience in investor relations, patient advocacy and product and corporate communications for life science companies will be important to us as we continue to progress toward the approval and launch of trilaciclib in small cell lung cancer.”Mr. Roberts brings nearly 30 years of broad communications and scientific research...

BLUE BELL, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) — REGO Payment Architectures, Inc. (“REGO”) (OTCQB:RPMT) today announced that it acquired Chore Check, LLC (“Chore Check”), on January 1st, 2021. Chore Check offers a chore-setting iOS app for families with 6-18 year olds, and Chore Check Pay membership provides linked accounts plus a prepaid debit Mastercard® for children. The Chore Check service has over 23,000 users, who will be migrated to REGO’s Digital Wallet Platform, MazoolaSM. Ada Vaughan, Chief Executive Officer, Chore Check said: “We’re so happy to bring Chore Check families to MazoolaSM so they can benefit from expanded features and the highest level of privacy for children’s information.” Peter S. Pelullo, Chief Executive Officer, REGO said: “This acquisition is an important add-on to our financial literacy agenda within...

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the company’s lead product candidate, PBGM01, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of infantile GM1 gangliosidosis (GM1). GM1 is a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available. The company expects to dose the first patient for...

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.11 January 2021 – The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company’s website at Autolus.13 January 2021 – The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor...

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021.8 January 2021 – Theresa Heggie, Chief Executive Officer, will join a panel – Broadening Gene Therapy – at the LifeSci Partners 10th Annual Healthcare Corporate Access Event from 10.00 am to 11.00 am ET, 3.00 pm to 4.00 pm GMT. A live audio webcast of the panel discussion will be available on the investor relations section of the Company’s website at Freeline.13 January 2021 –Theresa Heggie, Chief Executive Officer, will present...

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:39th Annual J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021 at 3:40 p.m. ET and a live webcast may be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay will be available for approximately 90 days following the presentation.H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021 at 6:00 a.m. ET at the conference website.About Cyclerion...

ORLANDO, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) — Today, we introduce Kontrol Energy Corp (CSE:KNR)(FSE:1K8)(OTCQB:KNRLF), a Canadian public company and a leader in smart buildings and cities technology. Simply put, Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.And its primary market is buildings. Big buildings.North American buildings waste up to $60 billion in energy every year. Worse yet, buildings account for up to 40% of Greenhouse Gas (GHG) emissions.  As the Company’s website declares, “It’s time for buildings to be Smarter.”Truth is, buildings that aren’t “connected” are the same buildings they were decades ago. They provide the basics: shelter, temperature control and safety at the same efficiency...

Proceeds from $35 Million Transaction to Reduce DebtContinues to be the Largest Operator of Class A and LPTV Stations in the U.S.NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) — HC2 Broadcasting Holdings, Inc., the broadcasting subsidiary of HC2 Holdings, Inc. (“HC2” or “the Company”) (NYSE: HCHC), announced today that HC2 Station Group, Inc. has completed the sale of three full power television stations and a low power television translator for $35 million. The stations included in the sale are KAZD Dallas, KYAZ Houston and KMOH-TV Phoenix, as well as KEJR-LD, which operates as a low power translator of KMOH-TV.HC2 has used the proceeds from the transaction to reduce HC2 Broadcasting’s debt. HC2 Broadcasting continues to have six television stations in Dallas, five stations in Houston and three stations in Phoenix as part of its network...

One of only two gaming properties to make the list alongside Amazon’s TWITCH.TVRanked #1 Gaming Information property for unique visitor traffic from mobile devicesTORONTO, Jan. 04, 2021 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings, Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV) is pleased to report that its owned and exclusive digital media property has been listed in the newly released Comscore ranking of Top 100 Properties in the United States. The ‘Comscore 100’ represents the largest owners of digital content across the Internet, from social media to search to ecommerce giants such as Google Sites, Facebook and Amazon Sites. The list is a significant milestone for direct advertising sales, and also serves as a filter within programmatic ad buying platforms to ensure brands run on the highest-quality...

–Once a day oral dosing with BT-11 induced placebo-adjusted clinical remission rates of up to 11.5% at week 12--A small subset of biologic-experienced patients also showed positive trends in clinical remission rates--Normalization of biomarkers such as fecal calprotectin observed after 2 weeks of oral dosing--BT-11 was well tolerated with a similar adverse event profile across placebo and BT-11 groups--Landos plans to initiate a Phase 3 trial of BT-11 in ulcerative colitis patients and a Phase 2 trial of BT-11 in Crohn’s disease patients in 2021-BLACKSBURG, Va., Jan. 04, 2021 (GLOBE NEWSWIRE) —  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced positive results from a first-in-patients 12-week Phase 2...